GlassScriptPhysician profile
Karim Anis
NPI 1285128702
$686.32
in general payments reported to CMS, 2019-2025
13 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $23.60 · 2023: $17.45 · 2024: $108 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $121.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.83 | 2025 | Jascayd, Ofev |
| Astrazeneca Pharmaceuticals LP | $83.49 | 2025 | Fasenra |
| Pulmonx Corporation | $68.14 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $57.26 | 2023-2024 | |
| Baxter Healthcare | $54.91 | 2025 | |
| Inogen, INC. | $36.20 | 2025 | |
| Grifols USA, LLC | $31.52 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $29.66 | 2025 | Zerbaxa |
| Verona Pharma, INC. | $27.54 | 2025 | Ohtuvayre |
| Amgen INC. | $25.30 | 2025 | Tavneos |
| Ambu INC. | $23.60 | 2022 | |
| United Therapeutics Corporation | $20.87 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Anis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.